Radius Health

228 articles with Radius Health

• 

  Celebrities are Bringing Awareness to Breast Cancer

  5/20/2022

  Celebrities' struggles with breast cancer are bringing new awareness to the importance of screening - particularly because new therapies like Radius Health's elacestrant are on the horizon.

• Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology

  5/19/2022

  The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced that data from the pivotal phase 3 EMERALD clinical trial (NCT03778931) evaluating elacestrant as a monotherapy vs. standard of care (SOC; fulvestrant or aromatase inhibitor, AI) for the treatment of ER+/HER2- advanced or metastatic breast cancer were published in the Journal of Clinical Oncology.

• Radius Health, Inc. First Quarter 2022 Results

  5/5/2022

  Radius Health, Inc., reported its financial results for the first quarter ended March 31, 2022.

• Radius Health to Release First Quarter 2022 Financial Results, Host Conference Call and Live Webcast on Thursday, May 5, 2022

  4/25/2022

  Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that it will release its first quarter 2022 financial results on Thursday, May 5, 2022.

• Radius Health Announces Leadership Appointments

  3/16/2022

  Radius Health, Inc., announced appointments to new roles on its executive leadership team, effective immediately.

• Radius Health Provides Business Update on Bone Health

  3/8/2022

  On December 15, 2020, Radius announced a discovery research collaboration with Massachusetts General Hospital to evaluate novel oral salt-inducible kinase inhibitors in an array of musculoskeletal diseases.

• Radius Health Files sNDA for TYMLOS® in Men with Osteoporosis

  3/1/2022

  Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) provided a business progress and regulatory update.

• Radius Health, Inc. Fourth Quarter & Full Year 2021 Results

  2/24/2022

  Radius Health, Inc., reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided key business and financial objectives for 2022.

• Radius Health to Release Fourth Quarter and Full Year 2021 Financial Results, Host Conference Call and Live Webcast on Thursday, February 24, 2022

  2/15/2022

  Radius Health, Inc. announced that it will release its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022.

• Radius Announces Update on TYMLOS® (abaloparatide) Label

  12/23/2021

  Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that the U.S. Food and Drug Administration (FDA) has approved updates to the TYMLOS label.

• Radius Health to Host Conference Call Today, Wednesday, December 8, 2021

  12/8/2021

  Radius Health, Inc. announced it will host a conference call , Wednesday, December 8, 2021, at 4:00 p.m. ET to cover the below.

• Radius Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal Women with Osteoporosis

  12/8/2021

  Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), today announced phase 3 topline results from the wearABLe study evaluating the non-inferiority (NI) of abaloparatide transdermal system (abalo-TDS) compared to abaloparatide subcutaneous injection (TYMLOS) in postmenopausal women with osteoporosis.

• Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021

  12/8/2021

  The Menarini Group and Radius Health presented today at the San Antonio Breast Cancer Symposium (SABCS). The data was presented as a “Late Breaker” and shared in an oral presentation by Dr. Aditya Bardia, MD.

• Radius Health to Participate in the Stifel 2021 Virtual Healthcare Conference

  11/11/2021

  Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that management will participate in the Stifel 2021 Virtual Healthcare Conference, including a fireside chat at 8:40 a.m. ET on Tuesday, November 16, 2021, followed by investor meetings.

• Radius Health, Inc.: Third Quarter 2021 Results

  11/8/2021

  Radius Health, Inc.Radius Health, Inc.Radius Health, Inc.Radius Health, Inc., reported its results for the third quarter ended September 30, 2021.

• 

  Clinical Catch-Up: October 18-22

  10/25/2021

  It was yet another busy week for clinical trial news. Here’s a look.

• Radius Health to Announce Third Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Monday, November 8, 2021

  10/20/2021

  Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its third quarter financial results on Monday, November 8, 2021.

• Radius Announces Positive Phase 3 Topline Results for TYMLOS® (abaloparatide) Subcutaneous Injection in Males with Osteoporosis

  10/18/2021

  Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), today announced positive topline results from the ATOM study evaluating abaloparatide 80mcg subcutaneous (SC) for use in males with osteoporosis.

• 

  Novel CAR T Therapies Help Celyad's CMO Bring Hope to Fearful Patients

  9/29/2021

  Celyad is focusing on advancing chimeric antigen receptor T cell (CAR T) therapies.

• Radius Health Business Update - July 27, 2021

  7/27/2021

  New patient adds for the U.S. TYMLOS business continue to grow. New TYMLOS patients in Q2, 2021 were up over 40% vs. the same period in 2020.